**FOI 9290 – Drugs**

Issued September 2024

**Q1a –  How many patients were treated with the following drugs from the following departments (for any disease)  from the start of Apr 2024 to the end of Jun 2024?**

***Please use the latest available 3 months if* April *to June is not available and specify which 3 months has been used.***

Please see below Pharmacy data from April 2024 to June 2024 as requested.

|  |  |  |
| --- | --- | --- |
| **Drug Name** | **Gastroenterology** | **Rheumatology** |
| **Adalimumab** | 118 | 414 |
| **Apremilast** | 0 | 9 |
| **Bimekizumab** | 0 | <5 |
| **Brodalumab** | 0 | 0 |
| **Certolizumab Pegol** | 0 | 16 |
| **Deucravacitinib** | 0 | 0 |
| **Etanercept** | 0 | 383 |
| **Guselkumab** | 0 | 0 |
| **Infliximab (Remicade)** | <5 | 8 |
| **Infliximab (Biosimilars)** | 113 | 39 |
| **Ixekizumab** | 0 | <5 |
| **Risankizumab** | 0 | 0 |
| **Secukinumab** | 0 | 76 |
| **Tildrakizumab** | 0 | 0 |
| **Ustekinumab** | 57 | 18 |
| **Upadacitinib** | 6 | 37 |
| **Vedolizumab** | 68 | 0 |
| **Filgotinib** | 16 | <5 |
| **Golimumab** | <5 | 92 |
| **Mirikizumab** | 0 | 0 |
| **Ozanimod** | 0 | 0 |
| **Etrasimod** | **0** | **0** |
| **Tofacitinib** | <5 | <5 |
| **Baricitinib** | 0 | 30 |
| **Rituximab** | 0 | 27 |
| **Sarilumab** | 0 | 0 |
| **Tocilizumab** | 0 | 130 |

**Q1b –  How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease)  from the start of Jun 2024 to the end of Aug 2024?**

***Please use the latest available 3 months if June to August is not available and specify which 3 months has been used.***

Please see below Pharmacy data from April 2024 to June 2024 as requested.

|  |  |  |
| --- | --- | --- |
| **Drug Name** | **Gastroenterology** | **Rheumatology** |
| **Ustekinumab (Stelara)** | 53 | 18 |
| **Ustekinumab (Pyzchiva)** | 0 | 0 |
| **Ustekinumab (Uzpruvo)** | 0 | 0 |
| **Ustekinumab (Wezenla)** | 0 | 0 |